SCHEMBL24791774

SCHEMBL24791774

CC(C)(C)OC(=O)N1CC(Oc2ccnc(CO)c2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.43
▸ JAK2 O60674 1/20 0.42
▸ JAK1 P23458 1/20 0.42
▸ GPR119 Q8TDV5 3/20 0.41
▸ LNPEP Q9UIQ6 7/20 0.41
▸ NR1H2 P55055 1/20 0.40
▸ PDE4B Q07343 1/20 0.40
▸ CACNB4 O00305 1/20 0.39
▸ CACNA1A O00555 1/20 0.39
▸ CACNA1G O43497 1/20 0.39
▸ CACNG3 O60359 1/20 0.39
▸ CACNA1F O60840 1/20 0.39
▸ CACNA1H O95180 1/20 0.39
▸ CACNB3 P54284 1/20 0.39
▸ CACNA2D1 P54289 1/20 0.39
▸ CACNG7 P62955 1/20 0.39
▸ CACNA1B Q00975 1/20 0.39
▸ CACNA1D Q01668 1/20 0.39
▸ CACNB1 Q02641 1/20 0.39
▸ CACNG1 Q06432 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30053592 1.00 USP30 (0.43) USP30JAK2JAK1GPR119LNPEP
SCHEMBL30111143 0.91 PIK3CD (0.48) USP30GPR119LNPEP
SCHEMBL29157077 0.91 PIK3CD (0.48) USP30GPR119LNPEP
SCHEMBL24791730 0.91 PIK3CD (0.48) USP30GPR119LNPEP
SCHEMBL29825830 0.89 GPR119 (0.54) GPR119LNPEPPDE4B
SCHEMBL28418810 0.86 USP30 (0.44) USP30GPR119CACNB4CACNA1ACACNA1G
SCHEMBL24793014 0.82 USP30 (0.46) USP30GPR119PDE4BCACNB4CACNA1A
SCHEMBL34476106 0.82 USP30 (0.46) USP30GPR119PDE4BCACNB4CACNA1A
SCHEMBL15000994 0.82 TNF (0.45) USP30GPR119NR1H2
SCHEMBL29826311 0.81 LNPEP (0.42) GPR119LNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4334304-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE Carmot Therapeutics, Inc. (US) 2024-03-13 — — EP disclosed
US-20220396569-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. 2022-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220396569-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE GLP1R, GIPR, GCGR USP30 2296/4885JAK2 591/4885JAK1 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback